Antoine Boustany, MD, MPH, MEM

Evolution of treatment targets in #IBD:

👉Stride 1 (2015)
👉Stride 2 (2021)
👉Stride 3 (2026)

Key differences, all in one table 👇

Two key studies in #IBD exploring elective appendectomy in the management of #UlcerativeColitis:

• ACCURE (2025)
• COSTA (2026)

Key differences summarized below 👇

With the rapid expansion of #IBD therapies, it is easy to lose track of which drugs are available and which are still in development

👉Understanding the different phases of clinical trials helps us make sense of what is coming next

Here is a simple visual summary 👇

My stepwise approach to #constipation:

1️⃣ Red flags, Medical Hx & Meds review 💊

2️⃣ Lifestyle/Dietary changes & Fibers 🍃

3️⃣ Osmotic laxatives 💦

4️⃣ Stimulant laxatives 💪

5️⃣ Secretaguogs +/- Prokinetics 🏹

6️⃣ Further tests❓

Meta-analysis of 4,697 #IBD patients with #Crohn’s:

👉Evaluated clinical & endoscopic response
👉Ileal CD: Lowest clinical remission
👉Ileal CD: Best efficacy with GSK
👉Colonic CD: Best efficacy with Upa
👉Efficacy of therapy varied by location

academic.oup.com/ibdjournal/adv…